US FDA panel to debate Cervarix approval, Gardasil use in males
This article was originally published in Scrip
Executive Summary
The US FDA's outside experts will convene on September 9th to consider the approvability of GlaxoSmithKline's cervical cancer vaccine Cervarix and a broader indication for Merck & Co's competitor Gardasil for vaccination of males.